Navigation Links
NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
Date:7/24/2008

SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The results revealed no unexpected safety findings and efficacy was maintained for the one-year duration of the study, as measured by the patients' global assessment scale. In addition, the results showed that the patients' mean blood pressure was stable for 52 weeks following the completion of the 301 study, suggesting that naproxcinod does not increase blood pressure over time. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

The 301 safety extension study was conducted in 92 clinical centers in the United States and enrolled the first 500 eligible patients with osteoarthritis of the knee who successfully completed the 301 phase 3 study for naproxcinod (see press releases of June 13, 2008 and November 12, 2007). NicOx expects to announce the top-line efficacy results from the ongoing 302 and 303 pivotal phase 3 studies for naproxcinod in the second half of 2008, ahead of a projected New Drug Application (NDA) in mid-2009.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "The data from this open label trial form an important part of our long term safety database for naproxcinod. We are happy with the good overall safety we have observed in this study and look forward to gaining further 52 week data from the 302 study, which includes an active control arm."

The 302 study is being conducted in patients with osteoarthritis of the knee and efficacy is being measured at 13 weeks by the same three co-primary endpoints as in the 301 and 303 studies. In addition, th
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
6. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
7. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
8. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
9. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
10. NicOx Naproxcinod ABPM Data Presented at American Heart Association
11. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015  Over the next five years, the ... grow, with ArcView predicting that 14 more states will legalize ... The U.S. market for legal cannabis grew 74 percent in ... Analysts project the market could grow more than fourfold to ... soften their stance on marijuana. Cannabiz Mobile Inc. ...
(Date:4/17/2015)... April 17, 2015 Today, the Pharmaceutical ... employees from 12 biopharmaceutical companies as "We Work ... policy advocacy and community service. Established ... Awards were created by the biopharmaceutical industry to ... their careers, but have also shown an outstanding ...
(Date:4/17/2015)... , April 17, 2015   IBA ... of radiopharmaceuticals, announced today that it has signed a ... North America, Inc. (IBAM NA), to Illinois Health and Science ... operate as an independent company headquartered in ... to take advantage of new product and footprint synergies. ...
Breaking Medicine Technology:Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... CareFusion will showcase its full portfolio of ... American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting ... (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) "The ... than ever, technology solutions must help increase safety and ...
... 5, 2011 OrbusNeich today announced that data published in ... Genous Stent is safe when accompanied by only 10 days ... trial involving 49 patients treated with Genous, no patient had ... cardiac death, myocardial infarction or angiographic evidence of stent thrombosis ...
Cached Medicine Technology:CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference 2CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference 3Data Published in EuroIntervention Indicate that OrbusNeich's Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy 2Data Published in EuroIntervention Indicate that OrbusNeich's Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy 3
(Date:4/18/2015)... Raleigh, NC (PRWEB) April 18, 2015 ... the risk of developing mesothelioma later in life, but ... ways from mesothelioma that is unrelated to radiation. Surviving ... study on its website. Click here to read ... and Australia compared the cases of 45 patients who ...
(Date:4/18/2015)... April 18, 2015 Aureus Medical ... staffing, including physical therapy jobs, has announced that ... South Carolina Physical Therapy Association Annual Conference to ... Center in Greenville, SC. , The SCAPTA ... exhibits with products and services. , Representatives ...
(Date:4/17/2015)... Bradley, Illinois (PRWEB) April 17, 2015 ... host a Party on the Patio from 2 p.m. ... which is located at 1320 Executive Ct. in Pekin, ... on Medicaid, who need some help to maintain their ... steel drums, and tropical treats will be served during ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... 2010) High doses of antioxidant nutritional supplements, such ... cells, which may predispose supplement-takers to developing cancer, according to ... The study, led by Eduardo Marbn, M.D., Ph.D., director ... the medical journal Stem Cells . The study ...
... find early stage cancers and precancerous growths than current ... -- Noninvasive stool DNA testing can detect two types ... in colon cancer prevention, say two new studies. , ... testing has higher detection rates for curable stage colorectal ...
... readmissions, study finds , TUESDAY, May 4 (HealthDay News) -- ... heart failure patient discharged from the hospital reduces the chance ... but that preventive measure is more often ignored than observed, ... 30,000 hospital patients covered by Medicare found that fewer than ...
... CINCINNATIThe popular diabetes medication metformin works in different fashion ... could lead to wider use of the drugparticularly in ... like tuberous sclerosis and lymphangioleiomyomatosis (LAM). The ... scientific director of UC,s Metabolic Diseases Institute, are published ...
... many times have you, after a particularly hard day, reached ... people, but for those trying to lose weight, it can ... programs never even address it. They focus on choosing ... key question: how can people who have eaten to cope ...
... ... cleaning machine that combines high impact cleaning efficiency with extended operating life, reduced life cycle ... can be completely stripped and rebuilt for maintenance ON-SITE in less than 15 minutes. ... (PRWEB) May 4, 2010 -- ...
Cached Medicine News:Health News:High doses of antioxidant supplements induce stem cell genetic abnormalities 2Health News:New Test for Colon Cancer Under Development 2Health News:Hospitals Falling Short on Heart Patients' Follow-Up Care 2Health News:Popular diabetes drug works differently than thought 2Health News:Managing the emotions behind eating 2Health News:BETE Fog Nozzle Announces HydroWhirl™ Orbitor – Clean-In-Place Rotating Tank Cleaning Machine with High Impact Cleaning for Extended Operating Life 2
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
Double Maddox...
Maddox Rod, short handle (12cm)...
... The Snellen chart remains to most ... range of different optotypes can be ... sheridan-gardner, landolt Cs, tumbling Es and ... column can be shown and a ...
Medicine Products: